1112 Breast Cancer After Breast Augmentation (BCABA): A National Multicentre Collaborative Study of Patient Management and Outcomes

Abstract

Abstract Aim The incidence of breast cancers diagnosed in patients that have previously had cosmetic breast augmentation is increasing. The presence of an implant at diagnosis poses management challenges. The largest UK series to date reports 49 patients from the iBRA study. We aimed to establish current UK practice encompassing both breast conserving surgery (BCS) and mastectomy +/- reconstruction, and its safety profile. Method A national multicentre collaborative model was used, with a steering committee from the NWBRC. Women diagnosed with breast cancer (invasive or non-invasive) from 2012 onwards with pre-existing implant augmentation were identified and data was recorded on REDCapâ. Outcomes were pathology and imaging findings, surgery performed, complications, and recommended adjuvant treatments. Recruitment will end in January 2024. Results An interim analysis representing 80% study accrual to date was performed. 24 collaborators from 23 UK units participated, identifying 144 women (median age 51 years, IQR 44-58). 124(86%) presented symptomatically and 20(14%) via screening. 103(72%) underwent BCS with 23(22%) requiring further excision. 84(82%) retained an implant and 98% of these patients were recommended for adjuvant radiotherapy. 41(28%) had mastectomy; 22(54%) had reconstruction (21 implant-based reconstruction, 1 autologous). Of the entire cohort, 6 patients returned to theatre within 90 days for a complication, and 3 lost an implant. Conclusions This is the largest reported series of these patients worldwide. There are wide variations in standard of care. Early analysis suggests that re-excision rates for patients undergoing BCS may be higher in this group. Complication rates are comparable to national standards.